Latest news

• Home-grown colorectal cancer drug approved in China

  treated previously with intravenous VEGF drugs, such as Roche’s Avastin (bevacizumab) and Lilly’s Cyramza (ramucirumab).

• Lilly buys Armo for $1.6bn to bolster immuno-oncology pipeline

  It also sells gastrointestinal cancer antibodies Erbitux (cetuximab) and recently launched Cyramza (ramucirumab).

• Baricitinib delay casts a pall over Lilly's results update

  reliance on older products such as Trulicity (dulaglutide) for diabetes and cancer drug Cyramza (ramucirumab).

• Lilly pitches Cyramza at bladder cancer

  The US-based pharma group said its RANGE study of Cyramza (ramucirumab) in patients with locally advanced, unresectable or metastatic urothelial carcinoma (mUC) - the most common form of bladder cancer - could

• Lilly promises solanezumab news in Alzheimer's 'before year-end'

  Among these, diabetes drugs Trulicity (dulaglutide) and Jardiance (empagliflozin) both saw solid sales gains that did not however meet analysts' expectations, while lung cancer therapy Cyramza (ramucirumab) fell 12% thanks to